12/12
09:34 am
prqr
ProQR Therapeutics (NASDAQ: PRQR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
12/12
09:34 am
prqr
ProQR Therapeutics (NASDAQ: PRQR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
12/12
09:17 am
prqr
Rating for PRQR
Medium
Report
Rating for PRQR
12/12
09:17 am
prqr
Rating for PRQR
Medium
Report
Rating for PRQR
12/12
08:26 am
prqr
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
12/12
08:26 am
prqr
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Medium
Report
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
12/12
07:46 am
prqr
Rating for PRQR
Low
Report
Rating for PRQR
10/29
09:25 am
prqr
Rating for PRQR
Medium
Report
Rating for PRQR
10/29
09:25 am
prqr
Rating for PRQR
Medium
Report
Rating for PRQR
10/29
09:02 am
prqr
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $14.00 price target on the stock, up previously from $6.00.
Medium
Report
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $14.00 price target on the stock, up previously from $6.00.
10/29
09:02 am
prqr
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $14.00 price target on the stock, up previously from $6.00.
Medium
Report
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $14.00 price target on the stock, up previously from $6.00.